Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Chapter 7/Androgen Excess Disorders <strong>in</strong> Women 137<br />
13. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome—views <strong>and</strong><br />
ideas. Hum Reprod 1997;12:1129–1137.<br />
14. Fulghesu AM, Villa P, Pavone V, et al. The impact of <strong>in</strong>sul<strong>in</strong> secretion on the ovarian response to<br />
exogenous gonadotrop<strong>in</strong>s <strong>in</strong> polycystic ovary syndrome. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1997;82:644–648.<br />
15. Dale PO, Tanbo T, Haug E, Abyholm T. The impact of <strong>in</strong>sul<strong>in</strong> resistance on the outcome of ovulation<br />
<strong>in</strong>duction with low-dose follicle stimulat<strong>in</strong>g hormone <strong>in</strong> women with polycystic ovary syndrome.<br />
Hum Reprod 1998;13:567–570.<br />
16. Dahlgren E, Friberg LG, Johansson S, et al. Endometrial carc<strong>in</strong>oma; ovarian dysfunction—a risk<br />
factor <strong>in</strong> young women. Eup J Obstet Gynecol Reprod Biol 1991;41:143–150.<br />
17. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence <strong>and</strong> predictors of risk for type 2 diabetes<br />
mellitus <strong>and</strong> impaired glucose tolerance <strong>in</strong> polycystic ovary syndrome: a prospective, controlled study<br />
<strong>in</strong> 254 affected women. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1999:84;165–169.<br />
18. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance <strong>and</strong> diabetes<br />
<strong>in</strong> women with polycystic ovary syndrome. Diabet Care 1999;22:141–146.<br />
19. Anonymous. American Diabetes Association: cl<strong>in</strong>ical practice recommendations 1997. Diabetes Care<br />
1997;20(Suppl 1): S1–S70.<br />
20. Reaven GM. Bant<strong>in</strong>g lecture 1988. Role of <strong>in</strong>sul<strong>in</strong> resistance <strong>in</strong> human disease. Diabetes<br />
1988;37:1595–1607.<br />
21. Haffner SM, Miett<strong>in</strong>en H, Gaskill SP, Stern MP: Metabolic precursors of hypertension. The San<br />
Antonio Heart Study . Arch Intern Med 1996;156:1994–2001.<br />
22. L<strong>in</strong>d L, Lithell H, Pollare T. Is it hyper<strong>in</strong>sul<strong>in</strong>emia or <strong>in</strong>sul<strong>in</strong> resistance that is related to hypertension<br />
<strong>and</strong> other metabolic cardiovascular risk factors? J Hypertens 1993;11(Suppl): S11–S16<br />
23. Talbott E, Clerici A, Berga SL, et al. Adverse lipid <strong>and</strong> coronary heart disease risk profiles <strong>in</strong> young<br />
women with polycystic ovary syndrome: results of a case-control study. J Cl<strong>in</strong> Epidemiology<br />
1998;51:415–422.<br />
24. Zimmermann S, Phillips RA, Dunaif A, et al. Polycystic ovary syndrome: lack of hypertension despite<br />
profound <strong>in</strong>sul<strong>in</strong> resistance. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1992;75:508–513.<br />
25. Holte J, Gennarelli G, Berne C, et al. Elevated ambulatory day-time blood pressure <strong>in</strong> women with<br />
polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996;11:23–28.<br />
26. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary<br />
syndrome <strong>and</strong> premature carotid atherosclerosis <strong>in</strong> middle-aged women. Arterio Thromb Vasc Biol<br />
(Onl<strong>in</strong>e) 2000:20(11):2414–2421.<br />
27. Chetkowski RJ, DeFazio J, Shamonki I, et al. The <strong>in</strong>cidence of late-onset congenital adrenal hyperplasia<br />
due to 21-hydroxylase deficiency among hirsute women. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1984;58:595–598.<br />
28. New MI, Speiser PW. Genetics of adrenal steroid 21-hydroxylase deficiency. Endocr Rev<br />
1986;7:331–349.<br />
29. Azziz R, H<strong>in</strong>capie LA, Knochenhauer ES, et al. Screen<strong>in</strong>g for 21-hydroxylase-deficient nonclassic<br />
adrenal hyperplasia among hyper<strong>and</strong>rogenic women: a prospective study. Fertil Steril 1999;72:915–925.<br />
30. New MI, Lorenzen F, Lerner AJ, et al. Genotyp<strong>in</strong>g steroid 21-hydroxylase deficiency: hormonal<br />
reference data. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1983;57:320–326.<br />
31. Speiser PW, Dupont J, Zhu D, et al. <strong>Disease</strong> expression <strong>and</strong> molecular genotype <strong>in</strong> congenital adrenal<br />
hyperplasia due to 21-hydroxylase deficiency. J Cl<strong>in</strong> Invest 1992;90:584–595.<br />
32. Azziz R, Dewailly D, Owerbach D. Cl<strong>in</strong>ical review 56: nonclassic adrenal hyperplasia: current concepts.<br />
J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab1994;78:810–815.<br />
33. Cizza G, Chrousos GP. Adrenocorticotrophic hormone-dependent Cush<strong>in</strong>g’s syndrome. Canc Treat<br />
Res 1997;89:25–40.<br />
34. Plotz CM, Knowlton AL, Ragan C. The natural history of Cush<strong>in</strong>g’s syndrome. Am J Med<br />
1952;13:597–605.<br />
35. Polson DW, Adams J, Wadsworth J, et al. Polycystic ovaries—a common f<strong>in</strong>d<strong>in</strong>g <strong>in</strong> normal women.<br />
Lancet 1988;1:870–872.<br />
36. Farquhar CM, Birdsall M, Mann<strong>in</strong>g P, et al. The prevalence of polycystic ovaries on ultrasound<br />
scann<strong>in</strong>g <strong>in</strong> a population of r<strong>and</strong>omly selected women. Aust NZJ Obstet Gynaecol 1994;34:67–72.<br />
37. Carm<strong>in</strong>a E, Koyama T, Chang L., et al. Does ethnicity <strong>in</strong>fluence the prevalence of adrenal<br />
hyper<strong>and</strong>rogenism <strong>and</strong> <strong>in</strong>sul<strong>in</strong> resistance <strong>in</strong> polycystic ovary syndrome? Am J Obstet Gynecol<br />
1992;167:1807–1812.<br />
38. Nestler JE. Role of hyper<strong>in</strong>sul<strong>in</strong>emia <strong>in</strong> the pathogenesis of the polycystic ovary syndrome, <strong>and</strong> its<br />
cl<strong>in</strong>ical implications. Sem<strong>in</strong> Reprod Endocr<strong>in</strong>ol 1997;15:111–122.